

Products renewal-Article 43 of Regulation (EC) No 1107/2009

CEUREG FORUM XIX, 5 -6 th November 2015

Rebecca Reboul

Institute for Plant Protection Products AGES, Austrian Agency for Health and Food Safety

Outline



- 1. Article 43- General considerations
- 2. Renewal procedures
- 3. Mixed products (> 1 a.s)
- 4. Outlook



Before



After renewal



1- Article 43- General considerations



Renewal of PPP Art. 43, GD SANCO/2010/13170 rev. 13

- application for renewal of PPP 3 months after Commission's decision ("date of application" DoA) of renewal of the a.s
- evaluation [compliance check + assessment] and decision on renewal of the PPP by zRMS - 6 months (including Peer review: 3 w.)
- decision on renewal of authorisations by cMS 3 months

!!! Applications by ALL authorisation holders!!! (notifying and non-notifying companies)

No application for renewal within 3 months or incomplete submissions: expiry of the authorisations or they will be revoked according to Art. 44 (3) and (4)



1- Article 43- General considerations



Preconditions for application according to Art. 43:

- no new uses!
- GAPs remain unchanged (what if the GAP has to be changed because of new end-points?)
- no formulation change! (except: non-significant change according to GD SANCO/12638/2011)
- no new cMS (for which the product is new)!

If preconditions are not fulfilled

- -> considered as a new PPP according to Art. 33
- -> new uses to be applied for after the renewal of the PPP, as an amendment according to Art. 33 or Art. 40

1- Article 43- General considerations



Challenges

- short timelines (for applicant as well as for MS)
- high number of PPP within a zone,
 high number of PPP with more than one a.s.
- new endpoints for the a.s. ...



HOWEVER... Possibility to extend timelines:

• Art. 43 (6): MS should extend the authorisation for the period necessary to complete the examination

In which case(s) does **extension** of authorisation apply? How long?



<u>Application:</u> Some (a lot of?) dossiers will **not be complete** due to lack of time to comply with **new data requirements**, **new endpoints**, **to complete long term or seasonal studies**, **or capacities of laboratories!**

Which data can be submitted later? (SANCO/2010/13170)

-> Cat. 4 studies

- studies related to new end points /time is insufficient to generate these studies (e.g. mesocosm studies, residue trials; efficacy trials if necessary because of changed end points -> lowering of amount active/ha)

MS may grant extension of the concerned authorisation until studies are made available


Cat. 1, 2, 3, 5 studies: eg: "formal" studies which do not impact the safety of the PPP



Application (Cat. 4 studies ongoing missing) should contain:

- all necessary studies available at the time of application
- list of studies to be generated, i.e. Cat. 4 studies, including time table for study submission and justification – to be accepted by the zRMS
- complete dRR, only once all studies are available max. 2 years
 - highlighting the changes to the risk assessment
 - old dRR acceptable for AIR 2 PPPs

-> 2 Steps application





- compliance check to be performed by each MS having authorisations,
 compliance with the conditions and restrictions of the active renewal
- where relevant´- applicant is non-notifier-: data matching check (PAI meeting, Sept 2015) to be performed by the zRMS (compensation studies, LoA or indications that studies will be provided)
- equivalence check(s) to be performed by the RMS for the active's renewal



Assessment:

- assessment to be performed by the zRMS
- -> begin of the evaluation only when dossier complete
- -> only new information <u>necessary</u> to be considered



- based on the dRR provided by the applicant (quality...)
- "new" consideration of the risk envelope approach for some sections like residues, fate (worst case: GAP for one PPP? other PPPs covered?)

Presubmission meeting !!!!

Not to forget: comparative assessment (Art 50) as well as data protection issues to be dealt at MS level





Risk Assessment:

relevant chapters only (for which new/changed endpoints are applicable),
 the others will NOT be considered -> latest Guidance to be applied

Efficacy:

- no assessment of efficacy (=no updated BAD)
- exception for "possible development of resistance or cross-resistance" to be presented in a new dRR (Section 7) (OECD KIII6.2.8)
- -> if GAP has to be changed because of risk assessment issues resulting from changed endpoints (i.e. necessary to lower the application rate/ha):
- new efficacy trials (reflecting the new GAP) might be necessary ("Cat. 4 studies")

3- Mixed products(>1 a.s.)



PPPs for which the period between the renewals of two a.s. is:

less than 1 year:

- -> evaluation only after the last a.s. has been renewed
- -> BUT application after each a.s. renewal
- -> dRR to be provided once the 2nd a.s. renewed

more than 1 year:

-> no need for an assessment of the additional actives in the PPP since no agreed endpoints are applicable, once the 2nd substance is renewed, there is no need to look at the 1st substance again

4- Outlook



Member States:

- Art 43 vs Art 33; Internal priority setting by authorities?
- strategy: comparative assessment (to be looked at asap)
- worksharing of MS (interzonal, within the zone)
- when evaluation of PPP ongoing before renewal of the a.s. and new EP are used, no article 43 necessary

Companies:

- reconsideration of the PPP portfolio, apply Art.40 in advance in some MS
- notification sheets to be sent: some PPP in the central zone are still without zRMS (no preference given by the applicant)
- quality of the dRR (old dRR acceptable for AIR2 PPPs/ completeness of information at the application)

4- Outlook



Implication for Data protection

- 30 months data protection from the renewal of the PPP (for a.s. and PPP data) - Art. 59
- if delayed submission of the complete dossier=> begin of the 30 months data protection with date of PPP renewal => max. 2y+1y evaluation

Situation for non-notifying companies

- application to be made 3 months after EI of a.s. renewal
- include a list of studies, justification why couldn t be made
- extension of the expiry date of the PPP in parallel to the reference PPP (if applied for)
- authorisation revoked at the renewal of the reference PPP
- new application Art 33 (based on Art. 34) as soon as data protection ok

4- Outlook



Implication for minor uses:

only for existing (authorised) minor uses

- when possible, e.g. authorisation holder is the data owner (residue data), evaluation to be performed by zRMS
- some cases, data owner (group of interest...) is not the authorisation holder and cannot prepare the dRR – solution has to be found at national level



Thank you for your attention

